Bancel Stephane 4

What Happened

• Stephane Bancel, a director of Generate Biomedicines (GENB), reported derivative transactions tied to the company's IPO. On March 2, 2026 he recorded conversions of derivative securities into common stock (acquired 724,160 shares; disposed 1,100,000 shares), and on February 26, 2026 he received a grant/award of 29,561 derivative shares. All transactions show $0.00 per share (non-cash conversions/awards); one conversion is reported as a disposition rather than a cash sale.

Key Details

• Transaction dates and prices:
  • Feb 26, 2026: Award/grant (A) of 29,561 shares @ $0.00 (derivative)
  • Mar 2, 2026: Conversion of derivative security (C) — acquired 724,160 shares @ N/A / $0.00
  • Mar 2, 2026: Conversion of derivative security (C) — disposed 1,100,000 shares @ $0.00
• Shares owned after transaction: not specified in the provided Form 4 details.
• Footnotes of note:
  • F1: Series A Preferred automatically converted into common on a 1-for-1.5190 basis upon the IPO closing on March 2, 2026.
  • F2: Some shares are held by OCHA LLC (Bancel is controlling unit holder); he disclaims beneficial ownership except to the extent of any pecuniary interest.
  • F3: The 29,561-share grant relates to an option whose underlying shares vest in full on Feb 19, 2027, subject to continued service.
• Filing: Report filed March 2, 2026 for transactions on/through March 2 — filing does not indicate lateness.

Context

• The $0.00 prices and the F1 note indicate these were corporate conversions/awards tied to the IPO (non-cash). Conversion (code C) means derivative securities (e.g., Series A preferred) were converted into common stock; a reported "disposed" conversion does not necessarily mean a market sale for cash.
• The 29,561-share award is derivative and subject to vesting (Feb 19, 2027). The OCHA LLC footnote clarifies an entity relationship and a disclaimer of beneficial ownership for some holdings.
• No 10b5‑1 plan, tax‑withholding, or cash proceeds are reported in this filing.